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Background: Neutrophil-to-lymphocyte ratio (NLR) has been shown to be a predictor of patients’ outcome for
several types of malignancies.
Findings: Using multicolor flow cytometry we searched for predictive markers to monitor blood immune cells in
patients with renal cell carcinoma undergoing surgery of the primary tumor. Due to a high standard deviation,
pre-surgery NLR values did not significantly differ between tumor patients and the control group. In contrast, the
granulocyte-to-dendritic cell (DC) ratio revealed significant higher values in tumor patients. Whereas NLR values
did not differ between patients with early stage tumors and locally advanced tumors, the granulocyte/DC ratio was
significantly different in these groups. Additionally, comparison of both ratios before and after tumor resection in
the two groups “open surgery” and “laparoscopy” could demonstrate the suitability of granulocyte/DC ratio as a
marker for immune monitoring.
Conclusions: Granulocyte/DC ratio may serve as a new putative biomarker for the immune monitoring of tumor
patients.
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Dendritic cellBackground
Renal cell carcinoma (RCC) is the most common malig-
nant tumor of the kidney and accounts for approximately
2-3% of all adult malignancies. More than 50% of all
renal cancers diagnosed are at a localized stage, however,
metastatic disease develops in 20-30% of patients with
localized disease [1]. Novel molecular targeted agents,
such as tyrosine kinase inhibitors or mammalian target
of rapamycin inhibitors change the treatment outcome for
patients with metastatic RCC from palliation to prolonga-
tion of life. Accurate prediction of long-term disease-free
survival immediately after surgical resection of the renal
tumor would be valuable for patient counseling, scheduling
follow-up imaging and identifying poor risk group patients
who might benefit from enrollment in adjuvant therapy
protocols. So far, tumor stage, tumor grade and patient* Correspondence: dagmar.riemann@uk-halle.de
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available predictors of the outcome of RCC patients [2].
There exist only few data on prognosis-relevant markers of
blood immune cells. A high number of granulocytes has
been associated with poorer prognosis in various cancers
including RCC [3] and neutrophil count was incorporated
into the Heng’s risk classification for metastatic RCC [4].
In our study blood immune cells were investigated in
RCC patients undergoing open or laparoscopic tumor
surgery. Using multicolor flow cytometry, we focused on
the neutrophil-to-lymphocyte ratio (NLR), which has been
shown to be a marker of systemic inflammatory response
and a predictor of patients’ outcome in this disease
[5,6]. We extended our study by the estimation of the
granulocyte-to-dendritic cell (DC) ratio as a new putative
marker. We compared patients’ data with an age-matched
control group, correlated pre-surgery markers with tumor
stages and performed time kinetics in patient groups
undergoing open or laparoscopic tumor surgery. Our data
suggest that the granulocyte/DC ratio is a more valuables an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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The study comprised 44 RCC (38 clear cell carcinoma)
patients that underwent surgery of the primary tumor at
the Department of Urology of the Martin Luther University
Halle-Wittenberg. 32 patients had stages < pT3 and 12
patients had locally advanced disease (≥pT3). The average
age was 66 years (range 43–86 years). 24 patients were
male and 20 were female. 27 patients were operated by
open surgery and 17 patients by laparoscopy. EDTA blood
was received from tumor patients one day before oper-
ation as well as on day 1, 3 and 7 after surgery. The whole
blood was analyzed directly, without any cryopreservation
or isolation of mononuclear cells. 20 individuals without
tumor disease in clinical history and with a mean age of
59 years (range 40–78 years) served as controls. The
study was performed with the approval from the Ethics
Committee of the Medical Faculty of the Martin Luther
University. Written informed consent was obtained
from the patients for the publication of this report and
any accompanying images.
Antibodies and Sample Preparation
Whole blood cell counts were measured with a Cell-Dyn
3200 (Abbott Laboratories, Wiesbaden, Germany). For
flow cytometric analysis, a lysed whole blood technique
with 4-color staining of blood cells was used. Lymphocytes
and granulocytes were identified on the basis of their
forward scatter (FSC) and side scatter (SSC) patterns to
get percentages of leukocytes. The staining for CD14
FITC (Beckmann Coulter, Krefeld, Germany) was used
to identify monocytes on a FL-1/SSC dot plot. Circulating
DC populations were identified with a “Blood DC Enu-
meration Kit” according to manufacturer’s instructions
(Miltenyi, Bergisch Gladbach, Germany). Briefly, aliquots
of whole blood were labeled with a cocktail of monoclonal
antibodies (mAbs) including anti-CD14-phycoerythrine
(PE)-Cy5 and anti-CD19-PE-Cy5 for a dump channel,
anti-CD1c-PE as a marker for type-1 myeloid DC (MDC1),
CD141/BDCA-3-APC (for MDC2) and CD303/BDCA-
2-FITC for plasmacytoid DC (PDC) [7]. After antibody
incubation, red cell lysis and washing steps, cells were
fixed. Flow cytometric data was acquired on a FACS
Calibur cytometer using CellQuest™ (BD Biosciences,
Heidelberg, Germany). On average, 1x10E6 leukocytes
were measured. Figure 1 gives a short overview on the
gating strategy for DC subtypes. Results are expressed
as percentages of DC in white blood cells or as absolute
numbers/μl of blood.
Absolute numbers of granulocytes and lymphocytes were
used to estimate the quotient NLR, absolute numbers ofgranulocytes and DC (as sum of MDC1, MDC2, and PDC)
for granulocyte/DC ratio.
Statistical analysis
Results are given as mean ± SE. Student’s t-test, Wilcoxon-
Mann–Whitney test, Kruskal-Wallis test and chi-squared
test were used to test for differences between groups.
All p-values are exploratory.
Findings
Comparison of immune cells in RCC patients and a
control group
In order to determine differences in the frequency of
immune cell subpopulations between RCC patients (before
surgery) and an age-matched control group, blood cells
were analyzed by 4-color-flow cytometry not only for
lymphocytes, granulocytes and monocytes but also for
DC subpopulations. As summarized in Table 1 there
was no significant difference in the number of leukocytes
between tumor patients and healthy donors, but patients
exhibited a higher percentage of granulocytes (68.8 ± 1.5
versus 61.4 ± 3.4% of leukocytes) and a lower percentage
of lymphocytes (23 ± 1.3 versus 27.8 ± 2.1% of leukocytes).
DC in peripheral blood are rare (<1% of leukocytes) and
the absolute DC numbers in RCC patients and the control
group only marginally varied (Table 1). The frequency
of all blood DC of RCC patients was lower than those
of control group (0.24 ± 0.02 versus 0.32 ± 0.03% of leuko-
cytes, p = 0.028). In particular the MDC1 subpopulation
was depressed in patients (p = 0.017), whereas no obvious
difference was found for MDC2 as well as for PDC.
Figure 2A illustrates that RCC patients had higher NLR
values, though this difference was not significant. In con-
trast, the granulocyte/DC ratio was significantly higher
in RCC patients compared to control group (p = 0.002;
Figure 2B).
Tumor stage-dependent alterations of the
immunophenotype
The preoperative immunophenotype of RCC patients with
‘early’ (<pT3) and advanced (≥pT3) stage tumors were
compared to investigate tumor stage-dependent alterations
(Table 1). The ≥ pT3 group had higher white blood cell
counts due to an increased number of granulocytes. Leu-
kocyte numbers correlated with tumor stages (p = 0.031).
The number of monocytes and lymphocytes were higher
in the advanced group (though not significantly), whereas
DC counts were lower. Patients with tumor stages < pT3
possessed 10.9 cells/μl MDC1 and 5.11 cells/μl PDC,
while 7.8 cells/μl MDC1 and 4.51 cells/μl PDC were
present in the advanced RCC stages ≥ pT3. Both the
absolute number and the frequency of DC (as percentage
of leukocytes) correlated with tumor staging (p = 0.009).
Despite the tumor progression was associated with
Figure 1 Gating strategy for the enumeration of blood DC. Top left: In a forward scatter (FSC)/side scatter (SSC) dot plot with all measured
cells a region P1 is drawn to exclude debris. Top right: In a SSC/PE-Cy5 dot plot gated on the P1 population a region P2 is drawn to exclude CD19
positive B cells, CD14 positive monocytes and the granulocytes (with high SSC properties). Down left: In a FL-1/FL-2 dot plot with the cells of population
‘P1 and P2’ a region is drawn around the BDCA-1-PE positive MDC1 cells (P3). Additionally, a region P4 defines the BDCA-2-FITC positive PDCs. Down
right: With the cells of population ‘P1 and P2’ a dot plot FL-1/FL-4 is created to define a region with the BDCA-3 strongly positive MDC2s (P5). An isotype
control staining involved in the kit helps to set regions in an optimal way. The sum of all blood DC was defined as ‘P1 and P2 and (P3 or P4 or P5)’.
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were observed comparing the NLR values of patients
with < pT3 and ≥ pT3 tumor stages due to the high
standard deviation (p = 0.607). However, granulocyte/
DC ratio was significantly increased in advanced tumor
stages (p = 0.001; Figure 2A).Table 1 Comparison of the pretreatment values of blood imm
healthy volunteers
Parameter Healthy donors
Number of leukocytes 6,260 ± 310
Granulocytes 4,227 ± 310
Monocytes 351 ± 39
Dendritic cells (DC) 19 ± 2
Lymphocytes 1,670 ± 111
Neutrophil-to-lymphocyte ratio (NLR) 2.86 ± 0.37
Granulocyte/DC ratio 249.4 ± 25
Data is given as cells/μl or as a quotient, with mean value ± SE.Comparison of post-operative changes in immune cells
between open surgery and laparoscopy
To investigate the immune competence of both patients’
groups, leukocytic subpopulations were measured before
(p) as well as one (d1), three (d3) and seven days (d7) after
surgery. Most patients showed post-operatively elevatedune cells of RCC patients with age-matched
RCC patients Patients < pT3 Patients ≥ pT3
7,005 ± 350 6,500 ± 402 8,340 ± 563
5,103 ± 292 4,702 ± 354 6,139 ± 385
375 ± 21 349 ± 22 441 ± 42
16 ± 1 17 ± 1 13 ± 2
1,566 ± 103 1,490 ± 110 1,760 ± 237
3.93 ± 0,40 3.8 ± 0.5 4.27 ± 0.64
378.7 ± 31 318.1 ± 30 535.4 ± 60
Figure 2 Comparison of NLR and granulocyte/DC ratio. NLR and granulocyte/DC ratio were compared between the control group and RCC
patients (all patients together, or with patients < pT3 and ≥ pT3), shown in (A). Comparison of both markers in RCC patients undergoing open
surgery or laparoscopy (B). An one-week time course of NLR and granulocyte/DC ratio is shown. Values of control group are illustrated as hatched
areas and as percentiles, with the 25th percentile (P25), P50 and P75. Significant differences between adjacent points are marked by an asterisk.
Riemann et al. Clinical and Translational Medicine 2014, 3:13 Page 4 of 6
http://www.clintransmed.com/content/3/1/13
Riemann et al. Clinical and Translational Medicine 2014, 3:13 Page 5 of 6
http://www.clintransmed.com/content/3/1/13leukocyte counts caused in particular by a short-time
increase of granulocytes, whereas the number of lym-
phocytes and DC dropped. During the post-operative
follow up, leukocytic subpopulations recovered, with a
faster normalization upon laparoscopy.
Both the preoperative NLR and the granulocyte/DC
ratio of patients started at or above the 75th percentile
of the control group (Figure 2B). NLR values showed a
similar course in both surgery groups, with an increase
at the first post-operative day and a slow recovery to
values of the pre-operative period within 7 days. One day
after surgery, the NLR value was 8.08 ± 0.67 in the open
surgery group and 6.86 ± 1.24 in laparoscopy (p = 0.348).
At day 7 after surgery both patients groups had again a
mean NLR level around the 75th percentile of the control
group. The difference in the course of DC counts was the
major cause for significant differences in the granulocyte/
DC ratio between patients with open surgery and laparos-
copy at day 3 (p = 0.007) and day 7 (p = 0.03; Figure 2B).
DC counts stayed < the 25th percentile of the control
group in open surgery, and increased to 133% of the
pre-operation value in the laparosopy group.
Discussion
Using multicolor flow cytometry, the immunophenotype
in the blood of renal cancer patients before and after
tumor surgery was analyzed to identify surrogate markers
for an immune monitoring. In earlier studies, we investi-
gated activation-associated lymphocytic markers as well as
monocytic markers, such as HLA-DR and CD13/amino-
peptidase N [8], while this study focused on the frequency
of leukocytic subpopulations in blood, in particular on DC
count. Pretreatment NLR as well as the granulocyte/DC
ratio were used as surrogate markers for the immuno-
phenotype. Comparing < pT3 stage RCC to ≥ pT3 tumor
stages, higher leukocyte counts were detected in advanced
tumor stages due to higher numbers of neutrophils. This
is in line with investigations identifying a high neutrophil
count as independent factor for poor prognosis in patients
with metastatic RCC receiving IL-2 [3] or anti-VEGF
(vascular endothelial growth factor) agents [9]. Tumors
are known to both drive myelopoiesis, sometimes leading
to a clinically apparent leukocytosis, and to inhibit the
differentiation of myeloid cells resulting in the accumu-
lation of immature myeloid cells [10]. Cancer-associated
myeloproliferation is not merely a paraneoplastic pheno-
menon of questionable importance, but leads to the
suppression of host immunity and promotion of tumor
angiogenesis. As an example, arginase-producing myeloid-
derived suppressor cells have been revealed as a granulo-
cytic subpopulation in RCC [11].
A high pretreatment NLR is associated with poor prog-
nosis for various cancers including RCC. Multivariate
analysis identified increased NLR as an independentprognostic factor for overall, but neither for cancer-
specific, nor for metastasis-free survival [5]. In sunitinib-
treated patients pre-treatment NLR has been discussed
to be associated with progression-free survival [12], and
sunitinib even decreases NLR [13]. Often, a NLR higher
than 5 has been considered as a critical value correlating
with poor prognosis in tumor patients [14]. In our patient
group a mean pretreatment NLR of 3.93 was found,
with 8 out of 44 patients reaching NLR values higher
than 5. However, NLR values showed a high variability
(1.2 to 14.4), which prevented a significant difference
between control group and tumor patients. Our results
showed that combining the number of granulocytes with
DC counts is a better approach to monitor immune de-
pression in RCC patients, generating more pronounced
differences than NLR. DC as cells specialized in antigen
processing and presentation become potent stimulators
of an adaptive immune response after undergoing the
critical process of maturation. Blood DC represent only
the 0.1–0.5% of leukocytes. Based on their lineage origin,
they can be divided into two major subsets, plasmacy-
toid DC as the major producers of type I interferon and
myeloid DC [15]. The blood DC counts decrease not only
with increasing age [16], but diminished DC frequency
and function was found in tumor disease, also in RCC
patients [17,18]. It is noteworthy that the frequency of
myeloid DC1 has been found to predict progression-free
survival in patients with advanced RCC treated with
sunitinib [18]. Our results confirm the suitability of
blood DC counts for an immune monitoring, and the
granulocyte/DC ratio raises differences between RCC
patients and control group, or between different tumor
stages.
Distinct peri-operative changes have been described in
RCC patients, e.g. a down-regulated intensity of mono-
cytic HLA-DR molecules [8]. Granulocytes increase post-
operatively and lymphocyte counts decrease, therefore
NLR increases at the first postoperative day with higher
values in the open surgery group. DC counts decreased
after surgery resulting in a raising granulocyte/DC ratio.
This marker stayed at high level in the “open surgery”
group for the whole observation period of one week,
whereas the marker reversed within short time in the
laparoscopy group, an observation, which needs further
investigation. Understanding the dynamics of DC release
and vascular distribution would provide key insights into
the process of immune suppression and reconstitution
after tumor surgery.
Conclusion
Taken together, our study implicates the granulocyte/DC
ratio as useful tool for monitoring the immunopheno-
type in RCC patients, e.g. for identifying poor risk group
patients who might benefit from enrollment in adjuvant
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this marker with clinical data, in particular with the
patients’ outcome, will be required in the future.
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